Anuh Pharma , a leading bulk drug manufacturing company, has reported a significant revenue growth of 21.14% for the first half of fiscal year 2026. The company's revenue increased to Rs 376.73 crores in H1 FY2026, up from Rs 310.98 crores in the same period last year.

Financial Performance

Despite the strong revenue growth, Anuh Pharma's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) remained nearly flat at Rs 75.20 crores, compared to Rs 73.43 crores in H1 FY2025. This indicates that while the company has been successful in expanding its top line, it has faced challenges in maintaining profit margins.

Operational Highlights

Anuh Pharma has recently expanded its manufacturing capacity, which now stands at 2400 MTPA (Metric Tonnes Per Annum) across 9 API (Active Pharmaceutical Ingredient) blocks and 2 intermediate blocks. This expansion is expected to contribute to the company's future growth and operational efficiency.

Future Outlook

The company remains optimistic about its performance in the second half of the fiscal year. Anuh Pharma expects margin recovery in H2 FY2026, driven by two key factors:

1. Operational efficiencies
2. Higher capacity utilization

These improvements are anticipated to help the company leverage its expanded manufacturing capacity more effectively.

Strategic Focus

According to the company's investor presentation, Anuh Pharma's growth strategy focuses on:

1. Market expansion
2. Addition of new products
3. Exploring inorganic growth opportunities

The company is particularly emphasizing innovation and the development of complex chemistry products, with a focus on lifestyle drugs addressing conditions such as diabetes, hypertension, and obesity.

Product Pipeline

Anuh Pharma has a robust pipeline of products under development, including:

• Ticagrelor (Anti-Platelet)
• Linagliptin and Empagliflozin (Anti-Diabetic)
• Pyronaridine Tetraphosphate and Piperaquine Phosphate (Anti-Malarial)
• Vonoprazon Fumarate (Anti-Ulcerative)
• Ethambutol, Pretomanid, and Bedaquiline Fumarate (Anti-TB)

This diverse product pipeline aligns with the company's focus on addressing various therapeutic areas and expanding its market presence.

Long-term Growth Projection

Looking ahead, Anuh Pharma has announced expectations for an annual growth rate ranging between 15% and 16%. This growth projection indicates the company's anticipated business expansion in its operations, leveraging its experienced team and robust resources in Research & Development and marketing.

As Anuh Pharma continues to navigate the challenges of maintaining profitability while expanding its revenue base, investors and industry observers will be keenly watching the company's performance in the second half of FY2026 to see if the expected margin recovery materializes and if the company can achieve its projected growth rate.

Anuh Pharma has released its financial results for the second quarter, showcasing a mixed performance with revenue growth but a decline in profitability.

Revenue Growth

The pharmaceutical company reported a revenue increase to ₹1.86 billion for the quarter, up from ₹1.65 billion in the same period last year, marking a year-over-year growth of 12.7%.

Profit Decline

Despite the revenue growth, Anuh Pharma experienced a significant drop in net profit:

The company's profitability metrics show a substantial decline, with net profit nearly halving compared to the same quarter in the previous fiscal year.

Half-Year Performance

For the half-year ended September 30, Anuh Pharma's financial highlights include:

Operational Highlights

• The company's cost of materials consumed increased to ₹2,554.15 crore in the current half-year, up from ₹2,067.07 crore in the same period last year.
• Employee benefits expense rose to ₹130.43 crore from ₹106.57 crore year-over-year.
• Other expenses increased to ₹399.91 crore from ₹353.23 crore in the previous year's first half.

Balance Sheet Position

As of September 30, Anuh Pharma's balance sheet shows:

• Total assets of ₹5,086.71 crore, a slight increase from ₹5,066.28 crore as of March 31.
• Current assets, including inventories and trade receivables, remained stable at ₹3,788.58 crore compared to ₹3,785.77 crore at the end of the previous fiscal year.
• The company's equity share capital doubled to ₹501.12 crore from ₹250.56 crore, due to the issuance of bonus shares in a 1:1 ratio during the quarter.

Conclusion

While Anuh Pharma is experiencing growth in its top line, it faces challenges in maintaining profitability. The increased costs, particularly in materials and other expenses, appear to be putting pressure on the company's margins. The company's ability to address these challenges while continuing to grow its revenue will be crucial in the coming periods.